Last reviewed · How we verify
NCT04903366
Absorption and Safety of Topical Timolol to Treat Chronic Wounds
trial testing Timolol Maleate in Glaucoma, Open-Angle in 40 participants. Completed in 14 January 2020.
9 March 2018
Quick facts
| Lead sponsor | VA Northern California Health Care System |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 21 November 2017 |
| Primary completion | 9 March 2018 |
| Estimated completion | 14 January 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Timolol Maleate — full drug profile →
Conditions studied
- Glaucoma, Open-Angle — all drugs for Glaucoma, Open-Angle →
- Chronic Wounds — all drugs for Chronic Wounds →
Sponsor
VA Northern California Health Care System
Who can join
18 and older, any sex, with Glaucoma, Open-Angle or Chronic Wounds. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Topical timolol has been used primarily as eye drops to treat glaucoma for many years. Recent clinical experience has broadened its off-label use for a number of skin conditions, including slow-healing wounds. While there have been extensive safety studies performed on timolol administration to treat the eye, to date, no studies have documented absorption of timolol after applied on chronic wounds. Thus, the purpose of this study is to determine the blood levels of timolol in patients after topical administration to a chronic wound, and compare these levels with those of patients after administration of the same drug formulation on the eye for the indication of glaucoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04903366
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Timolol Maleate
Trials testing the same drug.
- NCT04830397 — Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular H · Phase 2 · completed
- NCT03323164 — Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study · Phase 4 · completed
Other recruiting trials for Glaucoma, Open-Angle
Currently open trials in the same condition.
- NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension · Phase 2 · recruiting
- NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma · NA · recruiting
- NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial · Phase 3 · recruiting
- NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma · Phase 3 · recruiting
- NCT06058598 — Exercise Training in Patients With Glaucoma · NA · active not recruiting
Other VA Northern California Health Care System trials
Trials by the same sponsor.
- NCT03433222 — Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04903366 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Northern California Health Care System
- Last refreshed: 27 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04903366.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing